×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
CSLLY – csl ltd sp/adr (US:AMEX)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
CSLLY
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
10/28
03:08 pm
cslly
Transforming pharmaceutical R&D: the impact of digital technologies on drug discovery and development [Yahoo! Finance]
Low
Report
Transforming pharmaceutical R&D: the impact of digital technologies on drug discovery and development [Yahoo! Finance]
10/18
08:30 am
cslly
New Data Presented at IDWeek 2024 Show Adjuvanted and High-Dose Influenza Vaccines are Comparable in Protecting Adults 65 Years of Age and Older Against Seasonal Influenza
Low
Report
New Data Presented at IDWeek 2024 Show Adjuvanted and High-Dose Influenza Vaccines are Comparable in Protecting Adults 65 Years of Age and Older Against Seasonal Influenza
10/16
09:00 am
cslly
CSL Seqirus Presents Data at IDWeek 2024 Highlighting the Urgent Need to Increase Influenza Vaccination Rates and the Benefits of Cell-Based Influenza Vaccines
Low
Report
CSL Seqirus Presents Data at IDWeek 2024 Highlighting the Urgent Need to Increase Influenza Vaccination Rates and the Benefits of Cell-Based Influenza Vaccines
10/7
06:00 pm
cslly
Pharmanovia Acquires Exclusive Rights to Treatment for Parkinson’s Disease
Low
Report
Pharmanovia Acquires Exclusive Rights to Treatment for Parkinson’s Disease
10/4
12:30 pm
cslly
CSL Seqirus, a Global Leader in Pandemic Preparedness, Announces Sixth BARDA Award in Response to Avian Influenza
Low
Report
CSL Seqirus, a Global Leader in Pandemic Preparedness, Announces Sixth BARDA Award in Response to Avian Influenza
10/1
11:00 am
cslly
CSL Seqirus Presents Real-World Evidence at OPTIONS XII Conference Highlighting Effectiveness of Influenza Vaccinations
Low
Report
CSL Seqirus Presents Real-World Evidence at OPTIONS XII Conference Highlighting Effectiveness of Influenza Vaccinations
9/25
04:34 pm
cslly
CSL Seqirus, a Global Leader in Pandemic Preparedness, Announces Fifth BARDA Award in Response to Avian Influenza Outbreak [Yahoo! Finance]
Low
Report
CSL Seqirus, a Global Leader in Pandemic Preparedness, Announces Fifth BARDA Award in Response to Avian Influenza Outbreak [Yahoo! Finance]
9/25
04:30 pm
cslly
CSL Seqirus, a Global Leader in Pandemic Preparedness, Announces Fifth BARDA Award in Response to Avian Influenza Outbreak
Low
Report
CSL Seqirus, a Global Leader in Pandemic Preparedness, Announces Fifth BARDA Award in Response to Avian Influenza Outbreak
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/13
Commonwealth Bank of Australia (OTCMKTS: CSLLY) was upgraded by analysts at Jefferies Financial Group Inc from a "hold" rating to a "buy" rating.
22.0%
3/9 Australian shares dip into bear market territory [Reuters] 7.0%
4/8 Australia's CSL stands by profit guidance due to strong demand for blood products [Reuters] 6.4%
4/2 Commonwealth Bank of Australia (OTCMKTS: CSLLY) was upgraded by analysts at ValuEngine from a "sell" rating to a "hold" rating. 5.5%
4/27 Australian shares close higher on global stimulus hopes [Reuters] 3.7%
8/13 Australia shares join global rally as miners bounce, CSL gains [Reuters] 3.5%
2/18 Commonwealth Bank of Australia (OTCMKTS: CSLLY) was downgraded by analysts at Morgan Stanley from an "overweight" rating to an "equal weight" rating. 3.3%
1/10 Researchers decipher a new way that immune cells detect infections and cancers 2.9%
1/27 Commonwealth Bank of Australia (OTCMKTS: CSLLY) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 2.8%
10/14 Commonwealth Bank of Australia (OTCMKTS: CSLLY) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 2.5%
3/9 Australian shares dip into bear market territory [Reuters] 7.0%
4/8 Australia's CSL stands by profit guidance due to strong demand for blood products [Reuters] 6.4%
4/2 Commonwealth Bank of Australia (OTCMKTS: CSLLY) was upgraded by analysts at ValuEngine from a "sell" rating to a "hold" rating. 5.5%
4/27 Australian shares close higher on global stimulus hopes [Reuters] 3.7%
8/13 Australia shares join global rally as miners bounce, CSL gains [Reuters] 3.5%
2/18 Commonwealth Bank of Australia (OTCMKTS: CSLLY) was downgraded by analysts at Morgan Stanley from an "overweight" rating to an "equal weight" rating. 3.3%
1/10 Researchers decipher a new way that immune cells detect infections and cancers 2.9%
1/27 Commonwealth Bank of Australia (OTCMKTS: CSLLY) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 2.8%
10/14 Commonwealth Bank of Australia (OTCMKTS: CSLLY) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 2.5%
TOP News Decliners
2/24
Seqirus Receives FDA Approval for FLUAD® QUADRIVALENT (Influenza Vaccine, Adjuvanted) for Adults 65 Years and Older
-5.5%
4/21 CSL Behring Announces Results from Three Analyses of Hizentra® (Immune Globulin Subcutaneous [Human] 20% Liquid) in Primary Immunodeficiency (PI) -4.1%
12/9 HIZENTRA® (Immune Globulin Subcutaneous [Human] 20% Liquid) Receives Orphan-Drug Exclusivity for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) -1.4%
11/15 Commonwealth Bank of Australia (OTCMKTS: CSLLY) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -1.2%
10/7 Commonwealth Bank of Australia (OTCMKTS: CSLLY) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -0.8%
2/17 Commonwealth Bank of Australia (OTCMKTS: CSLLY) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $124.00 price target on the stock. -0.7%
9/4 Australian shares end lower on global growth worries, but NZ rises [Reuters] -0.3%
7/1 CSL Behring Delivers on its Promise to Advance Bleeding Disorder Treatment Research by Supporting 16 Data Presentations at ISTH 2019 -0.3%
4/9 Commonwealth Bank of Australia (OTCMKTS: CSLLY) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $110.00 price target on the stock. -0.3%
1/21 Forbes Magazine Ranks CSL Behring Among Best Employers for Diversity -0.2%
4/21 CSL Behring Announces Results from Three Analyses of Hizentra® (Immune Globulin Subcutaneous [Human] 20% Liquid) in Primary Immunodeficiency (PI) -4.1%
12/9 HIZENTRA® (Immune Globulin Subcutaneous [Human] 20% Liquid) Receives Orphan-Drug Exclusivity for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) -1.4%
11/15 Commonwealth Bank of Australia (OTCMKTS: CSLLY) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -1.2%
10/7 Commonwealth Bank of Australia (OTCMKTS: CSLLY) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -0.8%
2/17 Commonwealth Bank of Australia (OTCMKTS: CSLLY) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $124.00 price target on the stock. -0.7%
9/4 Australian shares end lower on global growth worries, but NZ rises [Reuters] -0.3%
7/1 CSL Behring Delivers on its Promise to Advance Bleeding Disorder Treatment Research by Supporting 16 Data Presentations at ISTH 2019 -0.3%
4/9 Commonwealth Bank of Australia (OTCMKTS: CSLLY) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $110.00 price target on the stock. -0.3%
1/21 Forbes Magazine Ranks CSL Behring Among Best Employers for Diversity -0.2%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: